Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Average Rating of “Buy” from Analysts

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have received an average recommendation of “Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $85.71.

A number of analysts have recently weighed in on the company. Cantor Fitzgerald assumed coverage on Structure Therapeutics in a research report on Tuesday, April 9th. They issued an “overweight” rating and a $65.00 price objective for the company. Lifesci Capital reissued an “outperform” rating on shares of Structure Therapeutics in a research report on Tuesday, February 27th.

Structure Therapeutics Trading Down 4.2 %

Shares of NASDAQ GPCR opened at $37.65 on Tuesday. The stock has a market capitalization of $1.75 billion and a PE ratio of -45.36. The stock’s fifty day simple moving average is $41.37 and its two-hundred day simple moving average is $48.87. Structure Therapeutics has a 12-month low of $21.79 and a 12-month high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.04. On average, equities analysts predict that Structure Therapeutics will post -0.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its stake in Structure Therapeutics by 404.0% in the 4th quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company’s stock worth $178,216,000 after acquiring an additional 3,504,747 shares during the last quarter. Avoro Capital Advisors LLC raised its stake in Structure Therapeutics by 133.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock worth $95,107,000 after acquiring an additional 1,333,333 shares during the last quarter. Federated Hermes Inc. raised its stake in Structure Therapeutics by 104.2% in the 4th quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company’s stock worth $92,411,000 after acquiring an additional 1,157,006 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in Structure Therapeutics by 835.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,799,923 shares of the company’s stock worth $90,752,000 after acquiring an additional 1,607,525 shares during the last quarter. Finally, FMR LLC raised its stake in Structure Therapeutics by 28.5% in the 3rd quarter. FMR LLC now owns 1,590,335 shares of the company’s stock worth $80,185,000 after acquiring an additional 352,600 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.